Filter News
Area of Research
News Topics
- (-) Biomedical (3)
- (-) Isotopes (4)
- 3-D Printing/Advanced Manufacturing (6)
- Advanced Reactors (7)
- Artificial Intelligence (12)
- Big Data (4)
- Bioenergy (4)
- Biology (5)
- Biotechnology (1)
- Buildings (1)
- Chemical Sciences (2)
- Climate Change (5)
- Computer Science (19)
- Coronavirus (2)
- Cybersecurity (17)
- Decarbonization (3)
- Energy Storage (1)
- Environment (4)
- Exascale Computing (1)
- Frontier (1)
- Fusion (8)
- Grid (4)
- High-Performance Computing (4)
- Machine Learning (12)
- Materials (2)
- Materials Science (6)
- Molten Salt (1)
- Nanotechnology (1)
- National Security (33)
- Neutron Science (6)
- Nuclear Energy (27)
- Partnerships (4)
- Physics (3)
- Quantum Science (1)
- Security (10)
- Simulation (1)
- Space Exploration (3)
- Summit (1)
- Sustainable Energy (3)
- Transformational Challenge Reactor (3)
- Transportation (1)
Media Contacts
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
A team of researchers has developed a novel, machine learning–based technique to explore and identify relationships among medical concepts using electronic health record data across multiple healthcare providers.
Radioactive isotopes power some of NASA’s best-known spacecraft. But predicting how radiation emitted from these isotopes might affect nearby materials is tricky
After its long journey to Mars beginning this summer, NASA’s Perseverance rover will be powered across the planet’s surface in part by plutonium produced at the Department of Energy’s Oak Ridge National Laboratory.
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.